Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T C Chan

Showing results (391-400 of 407) with videos related to

Pageof 41
Sort By:
The Lancet. Oncology|June 3, 2023
Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysisClaire Petit, Anne Lee, Jun Ma, et al.
Cancer|May 7, 2015
Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinomaEdwin P Hui, Brigette B Y Ma, K C Allen Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2018
Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized TrialsYu-Pei Chen, Ling-Long Tang, Qi Yang, et al.
Head & Neck|February 24, 2005
Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study GroupKwok Hung Yu, Sing Fai Leung, Stewart Yuk Tung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled TrialAnthony T C Chan, Edwin P Hui, Roger K C Ngan, et al.
Oncogene|December 2, 2010
FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulationV W Y Lui, D M-S Yau, C S-F Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, et al.
NEJM Evidence|February 6, 2024
Plasma Epstein-Barr Virus DNA and Risk of Future Nasopharyngeal CancerK C Allen Chan, W K Jacky Lam, Ann King, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trialA T C Chan, V H F Lee, R-L Hong, et al.
Journal of the National Cancer Institute|April 7, 2005
Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinomaAnthony T C Chan, S F Leung, Roger K C Ngan, et al.
Pageof 41

Showing results (391-400 of 407) with videos related to

Sort By:
Pageof 41
The Lancet. Oncology|June 3, 2023
Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysisClaire Petit, Anne Lee, Jun Ma, et al.
Cancer|May 7, 2015
Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinomaEdwin P Hui, Brigette B Y Ma, K C Allen Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2018
Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized TrialsYu-Pei Chen, Ling-Long Tang, Qi Yang, et al.
Head & Neck|February 24, 2005
Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study GroupKwok Hung Yu, Sing Fai Leung, Stewart Yuk Tung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled TrialAnthony T C Chan, Edwin P Hui, Roger K C Ngan, et al.
Oncogene|December 2, 2010
FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulationV W Y Lui, D M-S Yau, C S-F Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, et al.
NEJM Evidence|February 6, 2024
Plasma Epstein-Barr Virus DNA and Risk of Future Nasopharyngeal CancerK C Allen Chan, W K Jacky Lam, Ann King, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trialA T C Chan, V H F Lee, R-L Hong, et al.
Journal of the National Cancer Institute|April 7, 2005
Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinomaAnthony T C Chan, S F Leung, Roger K C Ngan, et al.
Pageof 41